Journal
ANTIVIRAL THERAPY
Volume 15, Issue 7, Pages 935-950Publisher
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1667
Keywords
-
Categories
Funding
- Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Decatur, GA, USA
- [2P30-AI-050409]
- [R01-AI-076535]
- [5R37-AI-041980]
- [5R37-AI-025899]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI041980, R37AI025899, P30AI050409, R01AI076535] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Nucleoside monophosphate prodrugs that are eventually bioconverted to the active nucleoside triphosphate (NTP) offer the potential to deliver increased intracellular NTP levels and/or organ-specific NIP enhancement. There are several classes of monophosphate prodrugs that have been applied to HCV drug discovery, and some of these approaches are currently being evaluated in humans. This review discusses recent advances in monophosphate prodrug approaches to improve oral absorption, stability and pharmacokinetic profile, including their advantages and potential pitfalls.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
